Fairvalue-Calculator Fairvalue-Calculator
EN DE

FluoGuide A/S, a clinical stage biotechnology company, (FLUO) Fair Value & Analysis

Healthcare · SE · Market cap 755M SEK

Pricekr 45.10
Fair Valuekr 15.02
Upside-66.7%
Quality95/100
Evidence: Low Range kr 11.26 – kr 18.77

Fair value as of: Jun 24, 2026

Analysis

FluoGuide A/S, a clinical stage biotechnology company, (FLUO) currently trades at kr 45.10, while our model-based Fair Value estimate is kr 15.02 — implying the stock looks roughly 66.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is FluoGuide A/S, a clinical stage biotechnology company, (FLUO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 15.02 versus a price of kr 45.10 — about −67% (overvalued). Model-based estimate, not financial advice.
What is the fair value of FLUO?
Our 21-model fair value for FluoGuide A/S, a clinical stage biotechnology company, is kr 15.02 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 45.10.
What is the quality score of FLUO?
FluoGuide A/S, a clinical stage biotechnology company, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.